Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
In Poland, drug-related public expenditure was first reported in 2012. The amounts reported include estimates for the funding of all non-governmental organisations that deal with demand reduction.
The central, regional and local governments reported drug-related expenditure, in the framework of the monitoring of the National Anti-Drug Strategy implementation. Estimates for 2014 and 2015 suggest that drug-related expenditure was at least EUR 25.8 million and EUR 35.5 million, respectively, amounting to least 0.01 % of the annual gross domestic product (GDP). However, these estimates do not include data from all units of the central government. Estimates for 2016 are expected in the near future.